Mediwound (NASDAQ:MDWD)‘s stock had its “buy” rating restated by analysts at HC Wainwright in a research note issued on Wednesday, AnalystRatings.com reports. They presently have a $5.50 price objective on the biopharmaceutical company’s stock. HC Wainwright’s price target suggests a potential upside of 105.99% from the stock’s current price.
A number of other research analysts have also recently commented on the company. Oppenheimer restated a “buy” rating and issued a $7.00 price target on shares of Mediwound in a research report on Tuesday. Zacks Investment Research raised Mediwound from a “hold” rating to a “buy” rating and set a $3.00 price objective on the stock in a research note on Saturday, June 20th.
Shares of NASDAQ MDWD opened at $2.67 on Wednesday. The company has a debt-to-equity ratio of 0.15, a quick ratio of 2.89 and a current ratio of 3.08. Mediwound has a 52 week low of $1.44 and a 52 week high of $4.14. The stock has a market capitalization of $72.63 million, a P/E ratio of 11.13 and a beta of 1.41. The stock’s fifty day moving average is $2.17 and its 200 day moving average is $2.42.
A number of large investors have recently added to or reduced their stakes in MDWD. Renaissance Technologies LLC boosted its stake in Mediwound by 42.0% in the fourth quarter. Renaissance Technologies LLC now owns 407,408 shares of the biopharmaceutical company’s stock valued at $1,263,000 after buying an additional 120,508 shares in the last quarter. Acadian Asset Management LLC boosted its stake in shares of Mediwound by 136.4% during the first quarter. Acadian Asset Management LLC now owns 130,072 shares of the biopharmaceutical company’s stock valued at $205,000 after purchasing an additional 75,045 shares in the last quarter. Fortis Advisors LLC acquired a new stake in shares of Mediwound during the first quarter valued at about $108,000. Sargent Investment Group LLC boosted its stake in shares of Mediwound by 51.5% during the first quarter. Sargent Investment Group LLC now owns 117,400 shares of the biopharmaceutical company’s stock valued at $184,000 after purchasing an additional 39,900 shares in the last quarter. Finally, Wells Fargo & Company MN boosted its stake in shares of Mediwound by 15.8% during the first quarter. Wells Fargo & Company MN now owns 219,386 shares of the biopharmaceutical company’s stock valued at $345,000 after purchasing an additional 29,911 shares in the last quarter. 22.86% of the stock is currently owned by institutional investors and hedge funds.
Mediwound Company Profile
MediWound Ltd., an integrated biopharmaceutical company, focuses on developing, manufacturing, and commercializing novel therapeutics products to address unmet needs. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns in the European Union, Israel, and Argentina.
Featured Article: Most Active Stocks: Dollar Volume vs Share Volume
Receive News & Ratings for Mediwound Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mediwound and related companies with MarketBeat.com's FREE daily email newsletter.